Related Experiment Video
Updated: Jun 13, 2026
07:01
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
Published on: April 17, 2013
Targeted therapy of thyroid cancer
1The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1432, Houston, TX 77030, USA. sisherma@mdanderson.org
Biochemical Pharmacology
|May 18, 2010
Summary
Novel therapies targeting angiogenesis show promise for advanced thyroid cancer. Tyrosine kinase inhibitors offer well-tolerated options, improving outcomes for patients unresponsive to conventional treatments.
Area of Science:
- Oncology
- Pharmacology
Background:
- Systemic chemotherapy for advanced or metastatic thyroid carcinomas has limited effectiveness.
- Novel therapeutic strategies are crucial for differentiated or medullary thyroid carcinomas unresponsive to conventional treatments.
Purpose of the Study:
- To review novel therapies, particularly those targeting angiogenesis, for advanced or metastatic thyroid carcinoma.
- To discuss the potential of tyrosine kinase inhibitors (TKIs) as well-tolerated treatment options.
Main Methods:
- Review of clinical trials and studies on novel agents for metastatic thyroid carcinoma.
- Focus on therapies targeting vascular endothelial growth factor receptors (VEGFRs) and associated kinases.
- Inclusion of agents targeting tumor vasculature, nuclear receptors, epigenetic abnormalities, and immune response.
Main Results:
- Partial response rates up to 30% reported in single-agent studies, with common prolonged disease stabilization.
- Sorafenib and sunitinib, approved for other cancers, show promising preliminary results in thyroid cancer.
- Ongoing randomized trials may lead to regulatory approval for several novel agents.
Conclusions:
- Novel agents, especially TKIs targeting VEGFRs, offer considerable promise for advanced thyroid cancer.
- These therapies are well-tolerated and may warrant regulatory approval.
- Clinical trial participation is emphasized for patients with metastatic or advanced thyroid carcinoma.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:20Synthesis and Regulation of Thyroid Hormones
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...